

1 **Distribution and functional implication of secretin in multiple brain regions**

2

3 Ruanna Wang<sup>1</sup>, Billy K C Chow<sup>2\*</sup> and Li Zhang<sup>1\*</sup>

4 <sup>1</sup> Joint International Research Laboratory of CNS Regeneration, GHM Institute of CNS  
5 Regeneration, Jinan University, Guangzhou, China

6 <sup>2</sup> School of Biological Sciences, University of Hong Kong, Hong Kong SAR, China

7 \* Correspondence: Dr. Li Zhang (zhangli\_sd@hotmail.com) or Prof. Billy K C Chow  
8 (bkcc@hku.hk)

9

10 **Abstract:**

11 Secretin is a polypeptide hormone initially identified for its gastrointestinal functions. However,  
12 emerging evidences show wide distribution of secretin and secretin receptor across various brain  
13 regions from cerebral cortex, hippocampus, hypothalamus to cerebellum. In this mini-review, we  
14 will firstly describe the region-specific expression pattern of secretin and secretin receptor in brain,  
15 followed by summary of central physiological and neurological functions mediated by secretin.  
16 Using genetic manipulation and pharmaceutical approaches, one can elucidate the role of secretin  
17 in mediating various neurological functions from simple behaviors such as water and food intake,  
18 to more complex functions including emotion, motor and learning or memory. At last, current  
19 weakness and future perspectives of secretin in central nervous system will be discussed, aiming  
20 to provide the potency of using secretin or its analog for treating various neurological disorders.

21

22 **Keywords: Secretin; Food and water intake; Motor learning; Stress; Anxiety; Transgenic**

23 **mice; Drug target**

24

## 25 **Expression of secretin and secretin receptor across brain regions**

26 Secretin has a unique place in the field of physiology as it is the first mammalian hormone  
27 proposed. Early work has established the release of secretin from duodenum to stimulate  
28 pancreatic secretion <sup>1</sup>. Later studies broaden its peripheral functions into fatty acid metabolism <sup>2</sup>,  
29 glucose homeostasis modulation <sup>3</sup>, bile acid secretion <sup>4</sup> and water reabsorption in renal collecting  
30 tubules <sup>5</sup>. In recent decades, multiple brain-gut peptide hormones such as vasoactive intestinal  
31 peptide (VIP), pituitary adenylate cyclase activating peptide (PACAP) and glucose-dependent  
32 insulintrophic polypeptide (GIP) have been found to be expressed in various brain regions <sup>6-8</sup>.  
33 Secretin, sharing high degree of sequence homology with those gut peptide hormones, also  
34 presents a wide spectrum of distributions in central nervous system.

35 The study for brain expression of secretin was initiated in 1979, when secretin-like bioactivity  
36 was firstly identified in porcine brain extracts <sup>9</sup>. The presence of secretin-like activity has been  
37 demonstrated across various mammalian species including canine, porcine and rats <sup>10</sup>. Further  
38 examination found immune-reactive secretin in multiple brain regions from forebrain cortex to  
39 midbrain and brain stem <sup>11,12</sup>. Increasing evidences from *in situ* hybridization (ISH) and  
40 immunohistochemistry (IHC) staining reveal region-specific expression pattern of secretin inside  
41 the brain. In a quick summary: (1) In cerebral cortex, secretin transcript <sup>13,14</sup> and immunoreactivity  
42 <sup>14</sup> have been found at a relatively lower level; (2) Hippocampal and hypothalamic neurons have  
43 expression of secretin gene transcript <sup>13,15</sup> and peptide <sup>15,16</sup>; (3) Within limbic system, secretin  
44 exists in amygdala nuclei especially central amygdala (CeA) <sup>17</sup>; (4) Cerebellar Purkinje cells and  
45 basket cells have prominent expression of secretin gene transcript <sup>14,15</sup> and peptide <sup>15,18,19</sup>; (5)  
46 Within brain stem, secretin is expressed in medullar oblongata, pons <sup>20</sup>, and nucleus of the tractus

47 solitary (NTS) <sup>17</sup>. These expression profiles are plotted mainly on rodent models, and a human  
48 brain study revealed similar results as secretin resides in cerebellar Purkinje cells, deep cerebellar  
49 nuclei, pyramidal neurons of motor cortex, plus hippocampal and amygdala nuclei <sup>21</sup>.

50 The spatial expression of secretin receptor has also been investigated. Early studies showed  
51 high affinity binding against secretin in rat brain membranes, indicating the existence of specific  
52 secretin receptor <sup>22</sup>. Using the more sensitive auto-radiographic binding approach, secretin binding  
53 sites have been found in brain stem, hippocampus, caudate, cerebellum, cingulate nuclei and  
54 orbital cortex <sup>23</sup>. Consistently, the region-specific RT-PCR study has identified secretin receptor  
55 within cerebellum, hippocampus, NTS, lateral dorsal thalamic nucleus, lamina terminalis, lateral  
56 habenular complex, supraoptic nucleus (SON) and paraventricular nucleus (PVN) of  
57 hypothalamus, and CeA <sup>17,24</sup>. Generally speaking, secretin receptor presents a much wider spatial  
58 distribution than secretin ligand <sup>14</sup>, indicating pleiotropic roles of secretin inside the brain via  
59 specific receptor binding within certain regions. A summary for major findings of secretin and  
60 secretin receptor across brain regions is shown in Figure 1.

61 In addition to spatial expression across brain regions, the temporal distribution of secretin and  
62 secretin receptor during development has also been investigated. Both secretin and secretin  
63 receptor gene display age-dependent expression patterns, with peak levels at early postnatal phase  
64 (before P7) in most of the brain regions examined <sup>17</sup>. During embryonic development, RT-PCR  
65 analysis has shown the existence of the secretin gene transcript in midbrain mesenchyme and  
66 tegmentum, cerebellar primordium and choroid plexus as early as E10.5 <sup>25</sup>. Using a similar ISH  
67 approach, the secretin receptor transcript is expressed in similar regions as those for secretin gene  
68 <sup>26</sup>. The early and persistent expression of secretin and secretin receptor since neural tube formation

69 strongly supports the role of secretin in neurodevelopment and neurological functions, as we will  
70 revise in later sections.

71

## 72 **Hypothalamic pathways for mediating water and food homeostasis**

73 As the regulating center for basic needs and vital functions of the body, hypothalamus is crucial  
74 for homeostatic control such as body osmolality, food intake, and energy expenditure. The known  
75 expression of secretin<sup>13</sup> and secretin receptor<sup>17</sup> within hypothalamus thus suggests the  
76 involvement of secretin in mediating body homeostasis. Indeed, the earliest evidence for central  
77 functions of secretin comes from hypothalamic regions, as intracerebroventricular (ICV) perfusion  
78 of secretin stimulates prolactin (PRL) and luteinizing hormone (LH) release<sup>27,28</sup>. These results  
79 were in line with electrophysiological recordings showing that secretin alters the firing rate of  
80 hypothalamic PVN neurons<sup>29</sup>, indicating the participation of secretin in activity-dependent  
81 neuroendocrine cell secretion. To elucidate whether it is peripheral or central originated secretin  
82 that plays a role, cultured hypothalamic explants were depolarized by KCl and endogenous release  
83 of secretin occurred in a calcium channel-dependent manner<sup>30</sup>. Therefore, secretin can be secreted  
84 from hypothalamic nuclei under stimuli to exert physiological or neurological functions via  
85 receptor binding inside the brain.

86 Secretin mediates water homeostasis via a central pathway. Secretin and secretin receptor are  
87 prominently distributed in posterior pituitary (pars nervosa) and in magnocellular neurons of  
88 hypothalamic SON and PVN<sup>31</sup>. Under plasma hyper-osmolality challenge, secretin is released  
89 from posterior pituitary, and can activate PVN and SON neurons to release vasopressin into the  
90 general circulation<sup>31</sup>. Further studies attribute angiotensin II (ANGII) as the upstream factor

91 mediating secretin's effect, as disruption of secretin-secretin receptor axis abolishes the dipsogenic  
92 effect of ANGII <sup>32</sup>. These two studies establish secretin as the linkage between ANGII and  
93 vasopressin, and the activation of ANGII-secretin-vasopressin axis counteracts hyper-osmolality  
94 stress by enhancing renal water reabsorption <sup>33</sup> and increasing water intake <sup>34</sup>. Such effects on  
95 water homeostasis are likely to be contributed by centrally but not peripherally released secretin,  
96 as ICV but not intraperitoneal (i.p) injection of secretin can induce water intake behavior <sup>35</sup>. These  
97 results plus early findings that identify secretin's direct role in facilitating renal tubular water  
98 reabsorption <sup>5</sup> thus demonstrate a dual role of secretin in water homeostatic regulation via both  
99 central and peripheral routes. However, these studies cannot answer the question of whether  
100 secretin directly regulates water intake via specific neural circuits. Previous findings showed that  
101 ICV-secretin infusion strongly activated subfornical organ (SFO) neurons <sup>35</sup>, whose activation is  
102 known to produce thirst sensation and water intake behavior <sup>34</sup>. Therefore, the hypothesis that  
103 secretin participates in water intake circuits can be tested in future, using selective activation of  
104 SFO neurons with secretin receptor expression.

105 Feeding or appetite control is known to be regulated by the melanocortin system in  
106 paraventricular nucleus (PVN) and arcuate nucleus (Arc) of hypothalamus <sup>36</sup>. Based on expression  
107 data of secretin and secretin receptor in these regions <sup>30,37</sup>, it is reasonable to speculate the function  
108 of secretin in mediating food intake behavior. Central administration of secretin activates Fos  
109 expression in PVN and Arc, and suppresses food intake in mice <sup>38</sup>. Further investigations  
110 demonstrate up-regulation of the melanocortin-4 receptor (Mc4r) pathway in PVN plus reduced  
111 agouti-related protein (AgRP) transcript levels in Arc <sup>38</sup>. These studies thus illustrate the anorectic  
112 role of secretin via central modulation on the melanocortin system. Unlike the scenario in water

113 intake, peripheral administration of secretin exerts similar effects on food intake suppression, PVN  
114 and Arc neuron activation, and Mc4r activation plus AgRP suppression in mice <sup>38</sup>. These results  
115 suggest that central and peripheral pathways co-exist to mediate food intake in parallel manners.  
116 Following studies find that peripheral secretin suppresses food intake via vagal afferent pathways  
117 projecting to Arc region <sup>39</sup>. In summary, secretin depresses appetite and food intake via both  
118 central modulation on the melanocortin system and vagal afferent pathways. However, whether it  
119 is central or peripheral secretin that plays more prominent roles in food intake regulation has not  
120 been resolved, and this can be differentiated using site-specific ablation of secretin. Moreover, the  
121 effect of secretin on food intake may be explained from other regions, as the stereotaxic injection  
122 of secretin into rat CeA also suppresses feeding behavior <sup>40</sup>.

123

#### 124 **Fine motor control and motor learning by secretin in cerebellum**

125 Both secretin and secretin receptor are prominently expressed in cerebellum, which is known to  
126 regulate complex motor tasks and related motor learning. In early studies, secretin gene transcript  
127 <sup>14</sup> and immunoreactivity <sup>19</sup> have been found to be present in rat cerebellum. Secretin binding  
128 affinity <sup>23</sup> and secretin receptor gene transcript <sup>17</sup> are also identified in rodent models. Later work  
129 using human cerebellar slices further reveals existence of secretin in Purkinje neurons, and  
130 secretin receptor in Purkinje cells plus basket interneurons <sup>21,41</sup>. Moreover, secretin is also found to  
131 be sparsely expressed in deep cerebellar nuclei <sup>15,19</sup>. It is thus proposed that secretin may modulate  
132 cerebellar function at multiple levels within local circuits.

133 The earliest evidence of secretin on cerebellar modulation comes from an electrophysiological  
134 study, in which secretin potentiates inhibitory postsynaptic current (IPSC) on Purkinje neurons of

135 cultured rat cerebellar slices<sup>18</sup>. Later studies confirm the release of secretin from Purkinje cells  
136 under KCl-induced depolarization<sup>42</sup>. Based on the presence of secretin immunoreactivity mainly  
137 in soma and proximal dendrites of Purkinje cells<sup>15,18,41</sup>, secretin is proposed to be released from  
138 excited Purkinje cells, and bind with its receptor on presynaptic basket interneurons, where it  
139 activates the cAMP-protein kinase A (PKA) pathway to open specific calcium channel for  
140 potentiating GABAergic transmission<sup>18</sup>. An alternative cellular pathway has been postulated as  
141 secretin can stimulate the release of glutamate from unknown sources to activate presynaptic  
142 GABAergic interneurons<sup>42</sup>. A third possible explanation states that secretin may suppress  
143 intracellular trafficking of Kv1.2 potassium channel in basket cells for potentiating presynaptic  
144 excitability<sup>43</sup>. Although the definitive cellular pathway has not been resolved, such retrograde  
145 neuromodulator function of secretin to potentiate GABAergic synaptic transmission<sup>44</sup> may help to  
146 prevent Purkinje cell from over-excitation by parallel fiber input, and may play crucial roles in  
147 maintaining firing patterns for timely and precise motor coordination and motor learning  
148 functions.

149 In consistent with these neuromodulation functions, behavioral evidences further support the  
150 role of endogenous secretin in mediating fine motor coordination and motor learning. When  
151 secretin receptor gene is deleted, those transgenic mice present impaired motor learning abilities  
152 on Rota-rod task<sup>45</sup>. A human study provides more convincing evidences as secretin infusion helps  
153 to improve eye blink conditioning, which is one classical cerebellar dependent learning<sup>46</sup>. Our  
154 group has developed a Purkinje-cell specific secretin mouse model using Cre-Loxp recombination  
155 approach and finds impaired performance on complex motor tasks such as vertical climbing, plus  
156 significant deficits in Rota-rod learning<sup>15</sup>. In another commonly applied behavioral paradigm for



157 evaluating cerebellar motor learning, eyeblink conditioning has also been found to be dependent  
158 on secretin, as acquisition but not extinction performance is impaired with infusion of a secretin  
159 receptor antagonist <sup>47</sup>. These behavior assays all support the role of cerebellar secretin in  
160 mediating complex motor tasks and motor learning.

161 Such motor modulation effects by secretin can also be interpreted by developmental regulation,  
162 in addition to neuromodulator functions as abovementioned. Secretin <sup>25</sup> and secretin receptor <sup>26</sup>  
163 expression has been found to exist in cerebellar primordium in early embryonic phase, and in  
164 postnatal phase <sup>17</sup>. We have recently studied juvenile mouse cerebellum and find that secretin and  
165 secretin receptor show peak expression level at early postnatal phase (P4-P7) <sup>48</sup>. IHC staining  
166 reveals secretin expression in the Purkinje cell body and proximal dendrite, whilst secretin  
167 receptor is distributed in Purkinje cell and granular cell progenitors <sup>48</sup>. As phenotypic evidences,  
168 we have shown that knockout of secretin gene from Purkinje cells results in a late onset of right  
169 reflex and negative geotaxis reflex, which are two motor reflexes highly dependent on cerebellar  
170 functions <sup>15</sup>. All these evidences support the involvement of secretin in cerebellar development.  
171 We thus perform morphological examinations on secretin-deficient mice, which show decreased  
172 number of Purkinje neurons, impaired dendritic arborization, plus lower spine density <sup>48</sup>. In a  
173 further examination of granular progenitor cells, we have shown their early onset of migration  
174 from external granular layer (EGL) toward internal granular layer (IGL) <sup>48</sup>. These results  
175 demonstrate that secretin modulates the postnatal development of both Purkinje cells and granular  
176 cells, thus affecting the formation and synaptic transmission of cerebellar cortical circuits. As  
177 Purkinje cell regulates the proliferation and maturation of granular cells <sup>49</sup>, further studies should  
178 be performed to delineate the role of Purkinje-derived secretin in mediating granular cell

179 progenitor proliferation and migration via cell-specific secretin gene deletion.

180 While regulating cerebellar neuron development, secretin may also have neuroprotective effects.

181 An early study has shown that the deprivation of secretin receptor significantly elevated

182 ethanol-induced apoptosis of EGL progenitor cells in cerebellum during early postnatal period <sup>50</sup>.

183 Elevated apoptosis has been recently found by our studies in the cerebellar EGL and IGL in

184 secretin-deficient mice <sup>48</sup>. Further mechanistic investigations show that secretin could activate

185 both PKA and extracellular signal regulated kinase (ERK) pathways to suppress apoptosis for

186 protecting granular cell progenitors <sup>48</sup>. In summary, our studies have illustrated the indispensable

187 role of secretin in mediating cerebellar-related motor coordination and motor learning functions,

188 which may be achieved via neuromodulator, neurodevelopmental and neuroprotective functions.

189 Recently, cerebellum has been proposed to be involved in multiple psychiatric disorders such as

190 autistic spectrum disorder (ASD) <sup>51</sup> or schizophrenia <sup>52</sup>, and has been shown to mediate cognitive

191 functions such as reward prediction <sup>53</sup>. Therefore, it should be valuable to further explore both

192 motor and non-motor functions of secretin in cerebellum.

193

#### 194 **Cognitive, emotional and social functions regulated by secretin**

195 In addition to water or food homeostasis by hypothalamus, and motor learning control in

196 cerebellum, secretin and secretin receptor are also found to be expressed across various regions in

197 limbic system, including hippocampus <sup>16</sup> and amygdala nuclei <sup>17</sup>. The hippocampus is known to

198 mediate spatial memory, whilst amygdala plays crucial roles in fear and anxiety control. Studies

199 have been performed to investigate the functional role of secretin in these regions. Using secretin

200 receptor-deficient mouse model, secretin has been demonstrated to modulate spatial memory

201 within Morris water maze task <sup>45</sup>. The authors proposed that such deficits in spatial memory were  
202 due to the impaired hippocampal CA1 spine formation and long-term potentiation (LTP)  
203 maintenance <sup>45</sup>, the latter of which can be replicated in a secretin-deficient mouse model <sup>16,54</sup>.  
204 Besides the CA1 region, the dentate gyrus (DG) also shows decreased neurogenesis and lower  
205 volume at early postnatal phase with secretin gene deletion <sup>54</sup>. These results on DG neurogenesis  
206 and CA1 neural plasticity all help to illustrate the function of secretin in spatial memory.

207 Emerging evidences have shown the participation of secretin in regulating emotions such as  
208 anxiety or fear. An early study using ICV perfusion of secretin into rat lateral ventricles found  
209 remarkably decreased locomotor activity in the open field <sup>55</sup>. The authors argued that such  
210 hypo-activity was due to suppressed propensity to initiate locomotor behaviors <sup>55</sup>, providing the  
211 first evidence of secretin in mediating emotional function. Another study has found that secretin  
212 infusion decreases the magnitude of fear conditioned startle reflex in rats <sup>56</sup>. Fear conditioning is  
213 well-known to be encoded by amygdala nuclei, and previous studies showed peripheral secretin  
214 injection activated Fos expression in rat CeA region <sup>57</sup>, providing a possible explanation for  
215 secretin-suppressed fear responses. In similar with fear regulation, secretin may also mediate  
216 anxiety or depressive behaviors. Central perfusion of secretin activates Fos expression in various  
217 brain regions including CeA, bed nucleus of the stria terminalis (BNST), external lateral  
218 subnucleus of parabrachial nucleus (PBel), locus coeruleus (LC), ventral periaqueductal gray  
219 (vPAG), paraventricular hypothalamus (PVH), lateral septal complex and anterior prefrontal  
220 cortex (PFC), and attenuates Fos immunoreactivity in dorsal periaqueductal gray (dPAG), lateral  
221 amygdala (LA), and parietal association cortex <sup>58</sup>. Those brain regions have been demonstrated to  
222 be involved in anxiety and depression disorder <sup>59</sup>, secretin thus may play crucial roles for mood

223 control. More interestingly, peripheral infusion of secretin exerts similar effects in a vagal  
224 dependent pathway <sup>57,60</sup>, suggesting the potency of gut-brain axis for emotion control. In  
225 consistent with animal studies, a human trial demonstrates amygdala activation after secretin  
226 infusion under affective stimuli <sup>61</sup>. In summary, secretin is highly related with the regulation of  
227 anxiety or depressive behaviors.

228 The role of secretin in mediating stress or anxiety can also be interpreted from neuromodulator  
229 and neuroendocrine aspects. The disruption of serotonin (5-HT) or dopamine systems has been  
230 implicated in psychiatric disorders such as major depression disorder (MDD). In studying the  
231 development of serotonergic neurons, it is interesting to find a transient expression of secretin in  
232 those nuclei since E14 to birth <sup>62</sup>, suggesting that secretin may be involved in the formation of  
233 brain 5-HT system, thus mediating emotion functions. Although no direct study has performed to  
234 examine the 5-HT level in secretin or secretin receptor knockout mouse, and those mice presented  
235 normal anxiety level at resting state <sup>15</sup>, future studies are still valuable to test the resilience toward  
236 environmental stress under deprivation of endogenous secretin. For dopamine metabolism, an  
237 early study found that secretin could increase the activity of tyrosine hydroxylase (TH) in rat  
238 superior cervical ganglion (SCG) <sup>63</sup>. A clinical finding shows that secretin infusion elevates brain  
239 dopamine turnover <sup>64</sup>. As TH is the rate-limiting step for biosynthesis of catecholamine including  
240 dopamine, epinephrine and norepinephrine, this mechanism may help to explain secretin's  
241 potential effects on modulating emotions. In summary, secretin potentially activates 5-HT and  
242 dopamine pathways across various brain regions to mediate anxiety or depressive behaviors,  
243 although direct evidence is still lacking. On the other hand, secretin may also work as one  
244 stress-induced hormone to mediate the hypothalamus- pituitary- adrenal (HPA) axis, which is

245 critical for both central and peripheral responses toward acute or chronic stress. Supporting  
246 evidences include that secretin could inhibit the release of adrenocorticotrophic hormone (ACTH)  
247 release and depress glucocorticoid responses to ACTH, thereby suppressing the HPA axis <sup>65</sup>. In  
248 addition, secretin is found to be up-regulated in rat hypothalamus under colchicine-induced stress  
249 <sup>37</sup>. These results collectively indicate that secretin may help to reduce stress and anxiety by  
250 mediating the 5-HT or dopamine system and the HPA axis.

251 Social function regulated by secretin has drawn a wide range of research interests. Using  
252 secretin receptor-deficient mouse model, it has been demonstrated that secretin modulates social  
253 behavior as reflected by the tube dominance and social recognition tests <sup>45</sup>. The wide spatial  
254 distribution of secretin further suggests that it could regulate social behavior at multiple nuclei.  
255 Currently available evidences mainly support the neuroendocrine module of secretin in social  
256 function. For example, peripheral secretin infusion activates oxytocin and vasopressin neurons in  
257 SON via the noradrenergic pathway <sup>66</sup>. As both oxytocin and vasopressin are known to mediate  
258 social behaviors, secretin thus may help to mediate social behavior via an endocrine manner.  
259 Further evidences reveal that central secretin activates SON neurons to release oxytocin into  
260 medial amygdala (MeA), where it binds with the local oxytocin receptor to improve social  
261 recognition in both rats and mice <sup>67</sup>. This study attributes secretin as the upstream mediator for  
262 oxytocin activation, and provides an alternative explanation for secretin's effects on social  
263 function. Besides those neuroendocrine functions, secretin may also mediate social behavior by  
264 directly regulating related neural circuits, since it is expressed in hippocampus, amygdala and  
265 hypothalamus.

266

267 **Implication of secretin in neurological diseases and pharmaceutical usage**

268 Due to its initially discovered peripheral functions, currently approved clinical usage of secretin  
269 mainly includes the intervention on gastrointestinal disorders. However, based on these  
270 abovementioned neurological functions, potential values of secretin in treating psychological or  
271 neurological disorders can be expected. The earliest report comes from intravenous infusion of  
272 secretin on ASD children, who are claimed to have improved social and communication behaviors  
273 <sup>68</sup>. A second study also shows improved scores in 7 out of 12 ASD children after secretin infusion  
274 <sup>64</sup>. Such results are somehow controversial as following similar clinical trials cannot replicate the  
275 improvement at most of the time. One pilot study even reports worsening scores of ASD patients  
276 during secretin treatment course <sup>69</sup>. Therefore, human studies still show controversial results  
277 regarding secretin's effects on ASD <sup>70</sup>. These are in sharp contrast with previous animal results  
278 showing modulation of social function by secretin <sup>45,67</sup>. Similar phenomena occur when secretin is  
279 used on schizophrenia patients: a single intravenous secretin injection leads to transient  
280 amelioration of symptoms, although overall scores are not improved <sup>71</sup>. In examining eye blink  
281 conditioning in schizophrenia patients, secretin has been found to improve such conditioned  
282 learning <sup>46</sup>. Secretin also partially reverses phencyclidine-induced deficits in prepulse inhibition  
283 (PPI) in an animal model <sup>72</sup>, suggesting its potential value as antipsychotics. We argue that the lack  
284 of persistent effects from secretin on ASD or schizophrenia patients may be due to the rapid  
285 metabolism of secretin, whose single injection thus cannot achieve long-lasting behavioral  
286 improvements. The development of new drug delivery approaches to achieve chronic release of  
287 secretin, or innovation of secretin analogs with a slow metabolic rate, may help to improve  
288 therapeutic effects.

289 To address the delivery route issue of secretin, the permeability of secretin across blood brain  
290 barrier (BBB) should firstly be addressed. General opinions agree that secretin could penetrate  
291 BBB via a non-saturation transmembrane diffusion <sup>73</sup>. Besides direct penetration across BBB,  
292 secretin may also activate the vagal system and mediate central neuron activation along vagal  
293 afferent nerves from brain stem to midbrain and limbic regions <sup>60</sup>. To avoid the blockade by BBB,  
294 another approach is to use intranasal drug delivery like those having been used for oxytocin <sup>74</sup>. It  
295 is interesting to find that intranasal application of secretin suppresses hyperactive and repetitive  
296 behaviors in mice, with even more significant effects comparing to ICV injection <sup>75</sup>. Therefore,  
297 intranasal administration may provide an alternative route for clinical usage of secretin.

298 Besides neuromodulator function, secretin may also work as a neuroprotective reagent. An  
299 animal study shows that secretin protects cerebellar and striatal neurons from ethanol-induced  
300 apoptosis at early postnatal phase <sup>50</sup>. In the hippocampal dentate gyrus (DG) region,  
301 secretin-deficient mice present decreased neurogenesis and lower volume at early postnatal phase,  
302 indicating reduced survival of neural progenitors <sup>54</sup>. These results are in line with our recent  
303 developmental studies showing that secretin could protect cerebellar granular progenitors from  
304 apoptosis during early postnatal phase <sup>48</sup>. Indeed, secretin-like neuropeptides have been identified  
305 as neuroprotective factors. For example, PACAP, with high sequence similarity with secretin,  
306 exerts strong neuroprotective effects against neural injury <sup>76,77</sup>. Therefore, secretin may be used as  
307 a drug candidate for protecting neurons.

308 In studying pharmaceutical potency of secretin, one should further illustrate the site-specific  
309 effects of secretin at cellular or even sub-cellular scale, plus its molecular pathway inside neurons.  
310 Emerging evidences are showing that secretin modulates neuron activity in region/cell-specific

311 manners. For example, secretin can potentiate synaptic transmission of NTS neurons <sup>78</sup> or  
312 cerebellar inhibitory interneurons <sup>18</sup>. In hypothalamus, secretin potentiates the firing rate of nearly  
313 half of PVN neurons whilst suppressing the other ~20% neurons' firing <sup>29</sup>. In similar, secretin  
314 infusion into CeA elevates half of neuron's firing rates whilst inhibits some neurons <sup>40</sup>. These  
315 diverged cell behaviors illustrate heterogeneous of neuron sub-populations, and the role of secretin  
316 is proposed to be dependent on cell identity and related electrophysiological properties. In  
317 studying intracellular pathways of secretin in brain, it is necessary to delineate the molecular  
318 mechanism of secretin receptor. Some interest findings challenge the classical belief that secretin  
319 receptor is activated on its monomer form. In specific, secretin receptor can form heterodimer with  
320 related G-protein coupled receptor (GPCR) such as AGNII receptor AT1aR, and such receptor  
321 dimer can bind with both ligands to activate the cAMP pathway in a synergistic way <sup>79</sup>. Using  
322 transmembrane peptides to specifically suppress the formation of such receptor heterodimer, an *in*  
323 *vivo* assay shows that secretin receptor dimerization plays a crucial role in facilitating water intake  
324 behavior <sup>79</sup>. This concept of receptor dimerization highlights the potency of secretin to modulate  
325 the physiological function of other related neuropeptides, by means of regulating receptor  
326 complex dynamic. For intracellular messengers of the secretin pathway, putative secretin receptor  
327 has been described in association with adenylate cyclase <sup>80</sup>, indicating the cAMP pathway as  
328 potentially downstream effectors. Such proposed model was later substantiated as adenylate  
329 cyclase activation occurs in frontal cortex <sup>81</sup>, hypothalamus and hippocampus under secretin  
330 infusion <sup>82</sup>. In summary, secretin activates cell surface receptor, probably in a hetero-dimer form,  
331 to elevate the intracellular cAMP level, which can further mediate various protein kinase pathways  
332 to affect neuron activity, neuroendocrine secretion and other cell behaviors.



333

### 334 **Conclusion and future perspective**

335 Since the discovery of secretin in brain extracts <sup>9</sup>, the central functions of secretin have been  
336 investigated for almost 40 years. To date, progresses of secretin as a neuropeptide mainly reside in  
337 the hypothalamic function of mediating food and water homeostasis, spatial memory related with  
338 hippocampus, plus cerebellar modulation for motor coordination and motor learning. In other  
339 behavioral paradigms, such as anxiety or depressive behavior, and social functions, incomplete or  
340 sometimes controversial evidences exist. A brief summary of well-established neural functions of  
341 secretin is listed in Table 1. Future studies should be performed to plot a more complete picture of  
342 secretin's expressional and functional profiles. For example, the function of secretin in cortex still  
343 lacks of comprehensive studies. One can observe expression of secretin <sup>21</sup> and secretin receptor <sup>23</sup>  
344 in cortical neurons especially pyramidal neurons. However, the exact role of secretin in cortical  
345 region is unknown yet.

346 One interesting question remains to be resolved, as whether there is a cell type-specific pattern  
347 of secretin expression. So far, the only partial answer comes from cerebellum, where secretin is  
348 found to be prominently in inhibitory Purkinje cells and some basket cells <sup>15</sup>. This issue is of  
349 critical importance for resolving central function of secretin, as brain nuclei is of high  
350 heterogeneity, and different cell subtypes play unique or sometimes antagonistic roles in mediating  
351 behaviors. The sub-typing of neurons by differential expression of neuropeptides has been well  
352 recognized. VIP, for example, is now regarded as one important marker for the specific sub-type  
353 of inhibitory neurons with unique electrophysiological property and circuitry connection. Secretin  
354 is thus expected to work in a similar way for differentiating between neuron sub-populations.

355 More importantly, these secretin-positive neurons are expected to have specific neural circuitry  
356 connection, which can help to elucidate specific neural functions.

357

### 358 **Acknowledgement**

359 We thank Dr. Lei Wang for revision of the whole manuscript. This study is funded by National  
360 Natural Science Foundation of China (#31500842) to L. Z., and by Hong Kong General Research  
361 Fund (GRF) grant (#17112317) to B.K.C.C.

362

363

### 364 **References:**

- 365 1 Bayliss, W. M. & Starling, E. H. The mechanism of pancreatic secretion. *The Journal of*  
366 *physiology* **28**, 325-353 (1902).
- 367 2 Sekar, R. & Chow, B. K. Secretin receptor-knockout mice are resistant to high-fat diet-induced  
368 obesity and exhibit impaired intestinal lipid absorption. *FASEB journal : official publication of*  
369 *the Federation of American Societies for Experimental Biology* **28**, 3494-3505,  
370 doi:10.1096/fj.13-247536 (2014).
- 371 3 Sekar, R. & Chow, B. K. Metabolic effects of secretin. *General and comparative endocrinology*  
372 **181**, 18-24, doi:10.1016/j.ygcen.2012.11.017 (2013).
- 373 4 Alpini, G. *et al.* Secretin activation of the apical Na<sup>+</sup>-dependent bile acid transporter is  
374 associated with cholehepatic shunting in rats. *Hepatology (Baltimore, Md.)* **41**, 1037-1045,  
375 doi:10.1002/hep.20653 (2005).
- 376 5 Chu, J. Y. *et al.* Phenotypes developed in secretin receptor-null mice indicated a role for  
377 secretin in regulating renal water reabsorption. *Molecular and cellular biology* **27**, 2499-2511,  
378 doi:10.1128/mcb.01088-06 (2007).
- 379 6 Ambati, S. *et al.* GIP-dependent expression of hypothalamic genes. *Physiological research* **60**,  
380 941-950 (2011).
- 381 7 Lam, K. S. & Srivastava, G. Sex-related differences and thyroid hormone regulation of  
382 vasoactive intestinal peptide gene expression in the rat brain and pituitary. *Brain research*  
383 **526**, 135-137 (1990).
- 384 8 Murase, T. *et al.* The expression of pituitary adenylate cyclase-activating polypeptide (PACAP)  
385 mRNA in rat brain: possible role of endogenous PACAP in vasopressin release. *Neuroscience*  
386 *letters* **185**, 103-106 (1995).
- 387 9 Mutt, V., Carlquist, M. & Tatemoto, K. Secretin-like bioactivity in extracts of porcine brain. *Life*  
388 *sciences* **25**, 1703-1707 (1979).

- 389 10 Chang, T. M., Berger-Ornstein, L. & Chey, W. Y. Presence of biologically and immunologically  
390 active secretin-like substance in the mammalian brain. *Peptides* **6**, 193-198 (1985).
- 391 11 Charlton, C. G., O'Donohue, T. L., Miller, R. L. & Jacobowitz, D. M. Secretin immunoreactivity  
392 in rat and pig brain. *Peptides* **2 Suppl 1**, 45-49 (1981).
- 393 12 O'Donohue, T. L., Charlton, C. G., Miller, R. L., Boden, G. & Jacobowitz, D. M. Identification,  
394 characterization, and distribution of secretin immunoreactivity in rat and pig brain.  
395 *Proceedings of the National Academy of Sciences of the United States of America* **78**,  
396 5221-5224 (1981).
- 397 13 Itoh, N., Furuya, T., Ozaki, K., Ohta, M. & Kawasaki, T. The secretin precursor gene. Structure  
398 of the coding region and expression in the brain. *The Journal of biological chemistry* **266**,  
399 12595-12598 (1991).
- 400 14 Ng, S. S., Yung, W. H. & Chow, B. K. Secretin as a neuropeptide. *Molecular neurobiology* **26**,  
401 97-107, doi:10.1385/mn:26:1:097 (2002).
- 402 15 Zhang, L., Chung, S. K. & Chow, B. K. The knockout of secretin in cerebellar Purkinje cells  
403 impairs mouse motor coordination and motor learning. *Neuropsychopharmacology : official  
404 publication of the American College of Neuropsychopharmacology* **39**, 1460-1468,  
405 doi:10.1038/npp.2013.344 (2014).
- 406 16 Yamagata, T., Urano, H., Weeber, E. J., Nelson, D. L. & Nishijima, I. Impaired hippocampal  
407 synaptic function in secretin deficient mice. *Neuroscience* **154**, 1417-1422,  
408 doi:10.1016/j.neuroscience.2008.04.037 (2008).
- 409 17 Tay, J., Goulet, M., Rusche, J. & Boismenu, R. Age-related and regional differences in secretin  
410 and secretin receptor mRNA levels in the rat brain. *Neuroscience letters* **366**, 176-181,  
411 doi:10.1016/j.neulet.2004.05.030 (2004).
- 412 18 Yung, W. H. *et al.* Secretin facilitates GABA transmission in the cerebellum. *The Journal of  
413 neuroscience : the official journal of the Society for Neuroscience* **21**, 7063-7068 (2001).
- 414 19 Koves, K., Kausz, M., Reser, D. & Horvath, K. What may be the anatomical basis that secretin  
415 can improve the mental functions in autism? *Regulatory peptides* **109**, 167-172 (2002).
- 416 20 Whitmore, T. E. *et al.* Human secretin (SCT): gene structure, chromosome location, and  
417 distribution of mRNA. *Cytogenetics and cell genetics* **90**, 47-52, doi:10.1159/000015658  
418 (2000).
- 419 21 Koves, K. *et al.* Secretin and autism: a basic morphological study about the distribution of  
420 secretin in the nervous system. *Regulatory peptides* **123**, 209-216,  
421 doi:10.1016/j.regpep.2004.04.026 (2004).
- 422 22 Freneau, R. T., Jr. *et al.* Secretin: specific binding to rat brain membranes. *The Journal of  
423 neuroscience : the official journal of the Society for Neuroscience* **3**, 1620-1625 (1983).
- 424 23 Nozaki, S. *et al.* In vitro autoradiographic localization of (125)I-secretin receptor binding sites  
425 in rat brain. *Biochemical and biophysical research communications* **292**, 133-137 (2002).
- 426 24 Toth, Z. E., Heinzlmann, A., Hashimoto, H. & Koves, K. Distribution of secretin receptors in the  
427 rat central nervous system: an in situ hybridization study. *Journal of molecular neuroscience :  
428 MN* **50**, 172-178, doi:10.1007/s12031-012-9895-1 (2013).
- 429 25 Siu, F. K., Sham, M. H. & Chow, B. K. Secretin, a known gastrointestinal peptide, is widely  
430 expressed during mouse embryonic development. *Gene expression patterns : GEP* **5**, 445-451,  
431 doi:10.1016/j.modgep.2004.09.001 (2005).
- 432 26 Siu, F. K., Sham, M. H. & Chow, B. K. The prenatal expression of secretin receptor. *Annals of*

433 *the New York Academy of Sciences* **1070**, 561-565, doi:10.1196/annals.1317.081 (2006).

434 27 Samson, W. K., Lumpkin, M. D. & McCann, S. M. Presence and possible site of action of  
435 secretin in the rat pituitary and hypothalamus. *Life sciences* **34**, 155-163 (1984).

436 28 Kimura, F., Mitsugi, N., Arita, J., Akema, T. & Yoshida, K. Effects of preoptic injections of  
437 gastrin, cholecystokinin, secretin, vasoactive intestinal peptide and PHI on the secretion of  
438 luteinizing hormone and prolactin in ovariectomized estrogen-primed rats. *Brain research*  
439 **410**, 315-322 (1987).

440 29 Chen, X. Y., Wang, H., Xue, Y. & Chen, L. Modulation of paraventricular firing rate by secretin  
441 in vivo. *Neuroscience letters* **532**, 29-32, doi:10.1016/j.neulet.2012.10.055 (2013).

442 30 Chu, J. Y., Yung, W. H. & Chow, B. K. Endogenous release of secretin from the hypothalamus.  
443 *Annals of the New York Academy of Sciences* **1070**, 196-200, doi:10.1196/annals.1317.012  
444 (2006).

445 31 Chu, J. Y. *et al.* Secretin as a neurohypophysial factor regulating body water homeostasis.  
446 *Proceedings of the National Academy of Sciences of the United States of America* **106**,  
447 15961-15966, doi:10.1073/pnas.0903695106 (2009).

448 32 Lee, V. H. *et al.* An indispensable role of secretin in mediating the osmoregulatory functions  
449 of angiotensin II. *FASEB journal : official publication of the Federation of American Societies*  
450 *for Experimental Biology* **24**, 5024-5032, doi:10.1096/fj.10-165399 (2010).

451 33 Boone, M. & Deen, P. M. Physiology and pathophysiology of the vasopressin-regulated renal  
452 water reabsorption. *Pflugers Archiv : European journal of physiology* **456**, 1005-1024,  
453 doi:10.1007/s00424-008-0498-1 (2008).

454 34 Zimmerman, C. A., Leib, D. E. & Knight, Z. A. Neural circuits underlying thirst and fluid  
455 homeostasis. *Nature reviews. Neuroscience* **18**, 459-469, doi:10.1038/nrn.2017.71 (2017).

456 35 Chu, J. Y., Cheng, C. Y., Lee, V. H., Chan, Y. S. & Chow, B. K. Secretin and body fluid homeostasis.  
457 *Kidney international* **79**, 280-287, doi:10.1038/ki.2010.397 (2011).

458 36 Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S. & Schwartz, M. W. Central nervous  
459 system control of food intake and body weight. *Nature* **443**, 289-295,  
460 doi:10.1038/nature05026 (2006).

461 37 Welch, M. G. *et al.* Secretin: hypothalamic distribution and hypothesized neuroregulatory  
462 role in autism. *Cellular and molecular neurobiology* **24**, 219-241 (2004).

463 38 Cheng, C. Y., Chu, J. Y. & Chow, B. K. Central and peripheral administration of secretin inhibits  
464 food intake in mice through the activation of the melanocortin system.  
465 *Neuropsychopharmacology : official publication of the American College of*  
466 *Neuropsychopharmacology* **36**, 459-471, doi:10.1038/npp.2010.178 (2011).

467 39 Chu, J. Y., Cheng, C. Y., Sekar, R. & Chow, B. K. Vagal afferent mediates the anorectic effect of  
468 peripheral secretin. *PloS one* **8**, e64859, doi:10.1371/journal.pone.0064859 (2013).

469 40 Pang, Y. Y., Chen, X. Y., Xue, Y., Han, X. H. & Chen, L. Effects of secretin on neuronal activity  
470 and feeding behavior in central amygdala of rats. *Peptides* **66**, 1-8,  
471 doi:10.1016/j.peptides.2015.01.012 (2015).

472 41 Lee, S. M., Yung, W. H., Chen, L. & Chow, B. K. Expression and spatial distribution of secretin  
473 and secretin receptor in human cerebellum. *Neuroreport* **16**, 219-222 (2005).

474 42 Lee, S. M., Chen, L., Chow, B. K. & Yung, W. H. Endogenous release and multiple actions of  
475 secretin in the rat cerebellum. *Neuroscience* **134**, 377-386,  
476 doi:10.1016/j.neuroscience.2005.04.009 (2005).

477 43 Williams, M. R., Fuchs, J. R., Green, J. T. & Morielli, A. D. Cellular mechanisms and behavioral  
478 consequences of Kv1.2 regulation in the rat cerebellum. *The Journal of neuroscience : the*  
479 *official journal of the Society for Neuroscience* **32**, 9228-9237,  
480 doi:10.1523/jneurosci.6504-11.2012 (2012).

481 44 Yung, W. H., Chan, Y. S., Chow, B. K. & Wang, J. J. The role of secretin in the cerebellum.  
482 *Cerebellum (London, England)* **5**, 43-48, doi:10.1080/14734220500416829 (2006).

483 45 Nishijima, I. *et al.* Secretin receptor-deficient mice exhibit impaired synaptic plasticity and  
484 social behavior. *Human molecular genetics* **15**, 3241-3250, doi:10.1093/hmg/ddl402 (2006).

485 46 Bolbecker, A. R. *et al.* Secretin effects on cerebellar-dependent motor learning in  
486 schizophrenia. *The American journal of psychiatry* **166**, 460-466,  
487 doi:10.1176/appi.ajp.2008.08040597 (2009).

488 47 Fuchs, J. R. *et al.* Cerebellar secretin modulates eyeblink classical conditioning. *Learning &*  
489 *memory (Cold Spring Harbor, N.Y.)* **21**, 668-675, doi:10.1101/lm.035766.114 (2014).

490 48 Wang, L., Zhang, L. & Chow, B. K. C. Secretin Modulates the Postnatal Development of Mouse  
491 Cerebellar Cortex Via PKA- and ERK-dependent Pathways. *Frontiers in cellular neuroscience*  
492 **11**, 382, doi:10.3389/fncel.2017.00382 (2017).

493 49 Basson, M. A. & Wingate, R. J. Congenital hypoplasia of the cerebellum: developmental  
494 causes and behavioral consequences. *Frontiers in neuroanatomy* **7**, 29,  
495 doi:10.3389/fnana.2013.00029 (2013).

496 50 Hwang, D. W., Givens, B. & Nishijima, I. Ethanol-induced developmental neurodegeneration  
497 in secretin receptor-deficient mice. *Neuroreport* **20**, 698-701,  
498 doi:10.1097/WNR.0b013e32832a5c9e (2009).

499 51 Wang, S. S., Kloth, A. D. & Badura, A. The cerebellum, sensitive periods, and autism. *Neuron*  
500 **83**, 518-532, doi:10.1016/j.neuron.2014.07.016 (2014).

501 52 Baumann, O. *et al.* Consensus paper: the role of the cerebellum in perceptual processes.  
502 *Cerebellum (London, England)* **14**, 197-220, doi:10.1007/s12311-014-0627-7 (2015).

503 53 Wagner, M. J., Kim, T. H., Savall, J., Schnitzer, M. J. & Luo, L. Cerebellar granule cells encode  
504 the expectation of reward. *Nature* **544**, 96-100, doi:10.1038/nature21726 (2017).

505 54 Jukkola, P. I., Rogers, J. T., Kaspar, B. K., Weeber, E. J. & Nishijima, I. Secretin deficiency causes  
506 impairment in survival of neural progenitor cells in mice. *Human molecular genetics* **20**,  
507 1000-1007, doi:10.1093/hmg/ddq545 (2011).

508 55 Charlton, C. G., Miller, R. L., Crawley, J. N., Handelmann, G. E. & O'Donohue, T. L. Secretin  
509 modulation of behavioral and physiological functions in the rat. *Peptides* **4**, 739-742 (1983).

510 56 Myers, K., Goulet, M., Rusche, J., Boismenu, R. & Davis, M. Inhibition of fear potentiated  
511 startle in rats following peripheral administration of secretin. *Psychopharmacology* **172**,  
512 94-99, doi:10.1007/s00213-003-1633-5 (2004).

513 57 Goulet, M. *et al.* A secretin i.v. infusion activates gene expression in the central amygdala of  
514 rats. *Neuroscience* **118**, 881-888 (2003).

515 58 Welch, M. G. *et al.* Secretin activates visceral brain regions in the rat including areas  
516 abnormal in autism. *Cellular and molecular neurobiology* **23**, 817-837 (2003).

517 59 Calhoon, G. G. & Tye, K. M. Resolving the neural circuits of anxiety. *Nature neuroscience* **18**,  
518 1394-1404, doi:10.1038/nn.4101 (2015).

519 60 Yang, H. *et al.* Peripheral secretin-induced Fos expression in the rat brain is largely vagal  
520 dependent. *Neuroscience* **128**, 131-141, doi:10.1016/j.neuroscience.2004.06.027 (2004).

521 61 Yurgelun-Todd, D. A. *et al.* Increased amygdala fMRI activation after secretin administration.  
522 *Experimental and clinical psychopharmacology* **16**, 191-198, doi:10.1037/1064-1297.16.3.191  
523 (2008).

524 62 Lossi, L. *et al.* Transient expression of secretin in serotonergic neurons of mouse brain  
525 during development. *The European journal of neuroscience* **20**, 3259-3269,  
526 doi:10.1111/j.1460-9568.2004.03816.x (2004).

527 63 McKeon, T. W. & Zigmond, R. E. Vasoactive intestinal peptide and secretin produce long-term  
528 increases in tyrosine hydroxylase activity in the rat superior cervical ganglion. *Brain research*  
529 **607**, 345-348 (1993).

530 64 Toda, Y. *et al.* Administration of secretin for autism alters dopamine metabolism in the central  
531 nervous system. *Brain & development* **28**, 99-103, doi:10.1016/j.braindev.2005.05.005  
532 (2006).

533 65 Nussdorfer, G. G., Bahcelioglu, M., Neri, G. & Malendowicz, L. K. Secretin, glucagon, gastric  
534 inhibitory polypeptide, parathyroid hormone, and related peptides in the regulation of the  
535 hypothalamus- pituitary-adrenal axis. *Peptides* **21**, 309-324 (2000).

536 66 Velmurugan, S., Brunton, P. J., Leng, G. & Russell, J. A. Circulating secretin activates supraoptic  
537 nucleus oxytocin and vasopressin neurons via noradrenergic pathways in the rat.  
538 *Endocrinology* **151**, 2681-2688, doi:10.1210/en.2009-1440 (2010).

539 67 Takayanagi, Y. *et al.* Activation of Supraoptic Oxytocin Neurons by Secretin Facilitates Social  
540 Recognition. *Biological psychiatry* **81**, 243-251, doi:10.1016/j.biopsych.2015.11.021 (2017).

541 68 Horvath, K. *et al.* Improved social and language skills after secretin administration in patients  
542 with autistic spectrum disorders. *Journal of the Association for Academic Minority Physicians :  
543 the official publication of the Association for Academic Minority Physicians* **9**, 9-15 (1998).

544 69 Robinson, T. W. Homeopathic Secretin in autism: a clinical pilot study. *The British  
545 homoeopathic journal* **90**, 86-91 (2001).

546 70 Sandler, A. D. *et al.* Lack of benefit of a single dose of synthetic human secretin in the  
547 treatment of autism and pervasive developmental disorder. *The New England journal of  
548 medicine* **341**, 1801-1806, doi:10.1056/nejm199912093412404 (1999).

549 71 Sheitman, B. B. *et al.* Secretin for refractory schizophrenia. *Schizophrenia research* **66**,  
550 177-181, doi:10.1016/s0920-9964(03)00068-9 (2004).

551 72 Myers, K. M., Goulet, M., Rusche, J., Boismenu, R. & Davis, M. Partial reversal of  
552 phencyclidine-induced impairment of prepulse inhibition by secretin. *Biological psychiatry* **58**,  
553 67-73, doi:10.1016/j.biopsych.2005.03.023 (2005).

554 73 Dogrukol-Ak, D., Tore, F. & Tuncel, N. Passage of VIP/PACAP/secretin family across the  
555 blood-brain barrier: therapeutic effects. *Current pharmaceutical design* **10**, 1325-1340  
556 (2004).

557 74 Bales, K. L. *et al.* Long-term exposure to intranasal oxytocin in a mouse autism model.  
558 *Translational psychiatry* **4**, e480, doi:10.1038/tp.2014.117 (2014).

559 75 Heinzlmann, A. *et al.* Intranasal application of secretin, similarly to intracerebroventricular  
560 administration, influences the motor behavior of mice probably through specific receptors.  
561 *Journal of molecular neuroscience : MN* **48**, 558-564, doi:10.1007/s12031-012-9839-9 (2012).

562 76 Tsuchida, M. *et al.* PACAP stimulates functional recovery after spinal cord injury through  
563 axonal regeneration. *Journal of molecular neuroscience : MN* **54**, 380-387,  
564 doi:10.1007/s12031-014-0338-z (2014).

565 77 Shioda, S. & Nakamachi, T. PACAP as a neuroprotective factor in ischemic neuronal injuries.  
566 *Peptides* **72**, 202-207, doi:10.1016/j.peptides.2015.08.006 (2015).

567 78 Yang, B., Goulet, M., Boismenu, R. & Ferguson, A. V. Secretin depolarizes nucleus tractus  
568 solitarius neurons through activation of a nonselective cationic conductance. *American*  
569 *journal of physiology. Regulatory, integrative and comparative physiology* **286**, R927-934,  
570 doi:10.1152/ajpregu.00600.2003 (2004).

571 79 Lee, L. T. *et al.* Transmembrane peptides as unique tools to demonstrate the in vivo action of  
572 a cross-class GPCR heterocomplex. *FASEB journal : official publication of the Federation of*  
573 *American Societies for Experimental Biology* **28**, 2632-2644, doi:10.1096/fj.13-246868 (2014).

574 80 Roth, B. L., Beinfeld, M. C. & Howlett, A. C. Secretin receptors on neuroblastoma cell  
575 membranes: characterization of 125I-labeled secretin binding and association with adenylate  
576 cyclase. *Journal of neurochemistry* **42**, 1145-1152 (1984).


577 81 Fremeau, R. T., Jr., Korman, L. Y. & Moody, T. W. Secretin stimulates cyclic AMP formation in  
578 the rat brain. *Journal of neurochemistry* **46**, 1947-1955 (1986).

579 82 Karelson, E., Laasik, J. & Sillard, R. Regulation of adenylate cyclase by galanin, neuropeptide Y,  
580 secretin and vasoactive intestinal polypeptide in rat frontal cortex, hippocampus and  
581 hypothalamus. *Neuropeptides* **28**, 21-28 (1995).


582

583

**(A) Secretin**



**(B) Secretin receptor**



584

585 **Figure 1 Spatial distribution of secretin and secretin receptor across major brain regions.**

586 This illustration is based on at least two independent studies revealing consistent results for either

587 protein or gene transcript expression. See main text for references. Abbreviations: CeA, central

588 amygdala; PVN, paraventricular nucleus; SON, supraoptic nucleus; Arc, arcuate nucleus; NTS,

589 nucleus of the tractus solitarius.

590



591 **Table 1 Summarized neurological functions of secretin**

<b>Behavioral modules</b>	<b>Major functions</b>	<b>Brain regions involved</b>	<b>References</b>
1. Water intake	Facilitation of water intake and renal water reabsorption	SFO, SON and PVN	31,32,35
2. Appetite	Suppressing food intake via mediating AgRP and Mc4r system	PVN and Arc	38,39
3. Motor learning	Mediating motor coordination and motor learning in Purkinje neurons	Cerebellar cortex	15,18,48
4. Spatial memory	Necessary for normal spatial memory via hippocampal synaptic plasticity	Hippocampal CA1	45,54
5. Social	Modulating social interaction and social recognition	Hippocampus, SON	45,67

592 **Abbreviations:** SFO, subfornical organ; SON, supraoptic nucleus; PVN, paraventricular nucleus;

593 Arc, arcuate nucleus.

594